Impact of oral azithromycin and intermittent preventive treatment with sulfadoxine-pyrimethamine regimen on child mortality in Sierra Leone: trial protocol for a randomised, two-arm, double-blinded, placebo-controlled clinical trial (ICARIA)
Authors:
- Kwabena Owusu-KyeiKOKwabena Owusu-Kyei
- Clara MenéndezCMClara Menéndez
- Icaria Trial TeamITIcaria Trial Team
Open Access
- 27 September 2024
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-13
Abstract
Azithromycin has been shown to be beneficial in preventing infectious diseases, including malaria, infectious diarrhoea and pneumonia. A cluster randomised control trial on azithromycin MDA in children in Niger, Malawi and Tanzania found a reduction in all-cause under-five (U5) mortality in communities who received azithromycin compared to placebo. However, the reduction was largest and statistically significant only in Niger. The purpose of this trial is to evaluate the impact of azithromycin plus intermittent preventive treatment in infants (IPTi), recently renamed by the World Health Organisation as perennial malaria chemoprevention (PMC), with sulfadoxine-pyrimethamine (SP) on all-cause mortality up to 18 months of age in children living in areas of high mortality burden through the Expanded Program on Immunisation (EPI) in Sierra Leone. The Improving Care through Azithromycin Research for Infants in Africa (ICARIA) trial is a phase III two-arm, individually randomised, double-blinded, placebo-controlled trial administering oral AZI (20 mg/kg bodyweight) at three time points to children attending EPI visits in Sierra Leone. A total of 20,560 infants attending the first EPI contact at around 6 weeks of age are recruited and randomised to AZI or placebo in a 1:1 ratio. The second and third AZI/placebo doses are given at 9 and 15 months of age. The primary outcome of the trial is all-cause mortality rate at 18 months of age assessed through mortality surveillance. Other trial outcomes include the impact on antimicrobial resistance, and on the immune response to certain key routine EPI immunisations, the safety of the intervention, the prevalence of SP resistance markers and the feasibility, and acceptability of adding AZI to the EPI programme. The trial will provide the evidence needed to inform policy regarding the adoption and large-scale implementation of AZI in areas of high-mortality burden in sub-Saharan Africa. ClinicalTrials.gov NCT04235816. Registered on 22 January 2020. Pan-African Clinical Trials Registry PACTR202004540256535. Registered on 14 April 2020.Keywords
All Related Versions
Funding Information
- Grand Challenges in Global Health (OPP1196642)
This publication has 26 references indexed in Scilit:
- Evaluation of health system readiness and coverage of intermittent preventive treatment of malaria in infants (IPTi) in Kambia district to inform national scale-up in Sierra LeoneMalaria Journal, 2021
- The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adultsCleveland Clinic Journal of Medicine, 2020
- Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distributionNature Medicine, 2019
- Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in AfricaNew England Journal of Medicine, 2019
- Methods for Studying Gut Microbiota: A Primer for PhysiciansJournal of Clinical and Experimental Hepatology, 2019
- Azithromycin to Reduce Childhood Mortality in Sub-Saharan AfricaNew England Journal of Medicine, 2018
- Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, TanzaniaEmerging Infectious Diseases, 2014
- Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trialsThe Lancet, 2009
- Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in NepalClinical Infectious Diseases, 2002
- Evaluation of a Medium (STGG) for Transport and Optimal Recovery of Streptococcus pneumoniae from Nasopharyngeal Secretions Collected during Field StudiesJournal of Clinical Microbiology, 2001